Atypical Antipsychotics (Second-Generation)
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Using this site does not create a doctor-patient relationship.
Drug information changes as the FDA updates labeling, and we cannot guarantee it is complete or current. Verify critical details with your pharmacist or physician.
Emergencies: If you think you may have a medical emergency, call 911 immediately. For a suspected overdose, call Poison Control at 1-800-222-1222. Report side effects to the FDA MedWatch program at fda.gov/medwatch or 1-800-FDA-1088.
See our Terms of Use and Editorial Policy.
Overview
Atypical (second-generation) antipsychotics are medications used to treat schizophrenia, bipolar disorder, and as adjunctive treatment for major depressive disorder. They differ from first-generation antipsychotics by having lower risk of extrapyramidal side effects due to their combined dopamine and serotonin receptor antagonism.
How do atypical antipsychotics (second-generation) work?
Atypical antipsychotics block dopamine D2 receptors (like first-generation antipsychotics) but also antagonize serotonin 5-HT2A receptors. This dual action is thought to reduce the risk of movement disorders (extrapyramidal symptoms) while maintaining antipsychotic efficacy. Individual agents vary in their affinity for additional receptors including histamine H1, muscarinic, and alpha-1 adrenergic receptors, which accounts for their differing side effect profiles.
Drugs in this class
- Quetiapine (Seroquel, Seroquel XR)
- Aripiprazole (Abilify, Abilify MyCite, Aristada)
- Ziprasidone (Geodon)